nach oben

Erschienen in:

12.07.2014 | Zertifizierte Fortbildung

Systemische Therapie des hepatozellulären Karzinoms

Stadienadaptierte Strategie

verfasst von: Dr. Nora Schweitzer, Prof. Dr. Arndt Vogel

Erschienen in: Im Fokus Onkologie | Ausgabe 7-8/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Multikinaseinhibitor Sorafenib ist die einzige zugelassene, systemisch wirksame Substanz bei fortgeschrittenem hepatozellulärem Karzinom. Neue molekulare Therapien sind in der klinischen Entwicklung, bisher aber mit meist negativen Ergebnissen. Es gilt nun, prognostische und prädiktive Faktoren für eine personalisierte Therapie zu identifizieren.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.PubMedCrossRef

Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012. International Agency for Research on Cancer, World Health Organisation, Lyon, Frankreich. 2014. http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx. Accessed 17 Jun 2014.

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.

Bruix J et al. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.PubMedCentralPubMedCrossRef

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, AWMF Registrierungsnummer: 032-053OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html.

Abou-Alfa GK et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.PubMedCrossRef

Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.PubMedCrossRef

Bolondi L et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Gastrointestinal Cancers Symposium. 2008. Abstr 129.

Bruix J et al. Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials. J Clin Oncol. 2009;27(Suppl 15):Abstr 4580.

10.

Craxi A et al. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: a sub-analysis from the SHARP trial. J Clin Oncol. 2008;26(Suppl 15).Abstr 15591.

11.

Galle P et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. J Hepatol. 2008;48(Suppl 2):Abstr 994.

12.

Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.PubMedCrossRef

13.

Ren Z et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol. 2012;30(Suppl 15):Abstr 4008.

14.

Lencioni R et al. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64(8):1034–41.PubMedCentralPubMedCrossRef

15.

Lencioni R et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular cinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012;66(7):675–83.PubMedCrossRef

16.

Lencioni R et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):17.CrossRef

17.

Marrero JA et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sortreated patients (pts): Clinical findings in pts with liver dysfunction. J Clin Oncol. 2013;31(Suppl):Abstr 4126).

18.

Iavarone M et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055–63.PubMedCrossRef

19.

Cheng AL et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75.PubMedCrossRef

20.

Bruix J et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol. 2009;50(Suppl 1):S28–S29.CrossRef

21.

Faivre S1 et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10(8):794–800.PubMedCrossRef

22.

Llovet JM et al. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. J Clin Oncol. 2013;31(28):3509–16.PubMedCrossRef

23.

Johnson PJ et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31(28):3517–24.PubMedCrossRef

24.

Philip PA et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–63.PubMedCrossRef

25.

Thomas MB et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110(5):1059–67.PubMedCrossRef

26.

Thomas MB et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843–50.PubMedCrossRef

27.

Ramanathan RK et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–83.PubMedCrossRef

28.

Zhu AX et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581–9.PubMedCrossRef

29.

Zhu AX et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol. 2012;23(Suppl 9):Abstr LBA2.

30.

O’Neil BH et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29(17):2350–6.PubMedCentralPubMedCrossRef

31.

Villanueva A et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–83.PubMedCentralPubMedCrossRef

32.

Zhu AX et al. EVOLVE-1: Phase 3 Study of Everolimus for Advanced HCC that Progressed During or After Sorafenib. J Clin Oncol. 2014;32(Suppl 3):Abstr 172.

33.

Birchmeier C et al. Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. Int Rev Cytol. 1995;120:221–66.CrossRef

34.

Kaposi-Novak P et al. Met-regulated expression signature defines a sub-set of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116(6):1582–95.PubMedCentralPubMedCrossRef

35.

Ueki T et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25(3):619–23.PubMedCrossRef

36.

Verslype C et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012; 30(Suppl):Abstr 4007.

37.

Santoro A et al. Tivantinib for second-line treatment of advanced hepato-cellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.PubMedCrossRef

38.

Bruix J et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49(16):3412–9.PubMedCrossRef

39.

Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.PubMedCrossRef

40.

Cainap C, Qin S, Huang W et al. Phase 3 trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2013;31(Suppl 4):Abstr 249.

41.

Velandia-Carrillo C et al. Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report. BMC Endocr Disord. 2014;14(1):26.PubMedCentralPubMedCrossRef

Titel: Systemische Therapie des hepatozellulären Karzinoms
Stadienadaptierte Strategie
verfasst von: Dr. Nora Schweitzer
Prof. Dr. Arndt Vogel
Publikationsdatum: 12.07.2014
Verlag: Urban & Vogel
Erschienen in: Im Fokus Onkologie / Ausgabe 7-8/2014
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI: https://doi.org/10.1007/s15015-014-0006-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Systemische Therapie des hepatozellulären Karzinoms

Stadienadaptierte Strategie

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7-8/2014

Dendritische Zellen stimulieren

Onkologen fordern Entbürokratisierung

Posaconazol in neuen Darreichungsformen

CLL-Rezidivtherapie für Multimorbide

PET verhindert unnötige Operationen

Neue Analyse der CRYSTAL-Studie zur Cetuximab-Therapie bei mCRC

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie